Physician profile
Joseph M Ebertz
NPI 1649224809
$1,680.44
in general payments reported to CMS, 2019-2025
12 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $107 · 2021: $392 · 2022: $681 · 2023: $94.99 · 2024: $115 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $180 · Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $179.99 |
| Food and Beverage | $135.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.62 | 2019-2022 | |
| Janssen Biotech, INC. | $313.21 | 2019-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $233.74 | 2019-2022 | |
| Genzyme Corporation | $154.32 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $96.52 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Vyne Pharmaceuticals INC. | $49.44 | 2020-2021 | |
| Lilly USA, LLC | $44.57 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $40.71 | 2020-2021 | |
| Incyte Corporation | $36.69 | 2022 | |
| Strata Skin Sciences, INC. | $13.66 | 2022 | |
| Galderma Laboratories, L.P. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ebertz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.